Supernus Pharmaceuticals, Inc. (SUPN)

Market Cap	2.04B
Revenue (ttm)	651.97M
Net Income (ttm)	59.71M
Shares Out	55.22M
EPS (ttm)	1.07
PE Ratio	34.50
Forward PE	20.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	484,145
Open	36.68
Previous Close	37.18
Day's Range	35.96 - 37.28
52-Week Range	25.53 - 39.37
Beta	0.90
Analysts	Hold
Price Target	36.00 (-2.47%)
Earnings Date	Nov 4, 2024

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 1, 2012
• Employees: 652
• Stock Exchange: NASDAQ
• Ticker Symbol: SUPN
• Website: https://www.supernus.com

Financial Performance

In 2023, Supernus Pharmaceuticals's revenue was $607.52 million, a decrease of -8.95% compared to the previous year's $667.24 million. Earnings were $1.32 million, a decrease of -97.83%.

Analyst Forecast

According to one analyst, the rating for SUPN stock is "Hold" and the 12-month stock price forecast is $36.0.

Price Target

$36.0

(-2.47% downside)

Analyst Consensus: Hold